TABLE 2.
Summary of best overall response, overall response rate, and duration of response by investigator assessment (measurable disease) among 219 women with HER2‐positive advanced breast cancer treated with pertuzumab + trastuzumab + chemotherapy (PTC) or trastuzumab + chemotherapy (TC)
| PTC (N = 90) | TC (N = 92) | |
|---|---|---|
| Best overall response, n (%) | ||
| CR | 0 (0.0) | 0 (0.0) |
| PR | 17 (18.9) | 18 (19.6) |
| SD | 57 (63.3) | 49 (53.3) |
| PD | 13 (14.4) | 20 (21.7) |
| Unknown | 1 (1.1) | 3 (3.3) |
| Missing | 2 (2.2) | 2 (2.2) |
| Overall response rate (CR + PR), n (%) | 17 (19.5) | 18 (20.7) |
| (upper limit 95% CI) | (27.9) | (29.1) |
| Odds ratio for overall response (upper limit 95% CI) | 0.957 (1.778) | |
| Duration of response (CR + PR) | n = 17 | n = 18 |
| Median (upper limit 95% CI), months | 8.3 (18.2) | 4.1 (13.4) |
| Unstratified HR (95% CI upper limit) | 0.490 (0.945) | |
| Stratified HR (95% CI upper limit) | 0.656 (1.369) | |
Abbreviations: CI, confidence interval; CR, complete response; HR, hazard ratio; PD, progressive disease; PR, partial response; SD, stable disease.